by Truveta staff | Jan 31, 2024 | Data
Clinical trials and registries have traditionally been the gold standard for high-quality healthcare data, offering complete longitudinal records across data domains in a clean, analysis-ready format. However, achieving this level of quality involves significant...
by Truveta staff | Jan 26, 2024 | Research
Truveta Research explored the rates of pediatric RSV immunizations and pediatric RSV-associated hospitalizations for children under the age of two. Of the 1,872,292 children under age two who were eligible to receive an RSV immunization, 3.7% of the eligible...
by Truveta staff | Jan 25, 2024 | News
Today Truveta is excited to announce that the company is a finalist at the 2024 South by Southwest (SXSW) Innovation Awards recognizing Truveta Language Model (TLM) in the Artificial Intelligence (AI) category. This prestigious accolade not only acknowledges...
by Truveta staff | Jan 23, 2024 | Research
Overall, the rate of hospitalizations associated with respiratory viruses continues to increase (92.8% increase from November 2023 to the end of December 2023). The largest increases in hospitalizations over the past month were associated with influenza (251.7%...
by Truveta staff | Jan 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) have remained stable in the last 3 months, with rates in December 2023 about the same as rates in November 2023 and October 2023. For the anti-diabetic medications (ADMs), the number of...
by Truveta staff | Jan 22, 2024 | News
Truveta, a growing collective of 30 health systems with a shared mission of Saving Lives with Data, was awarded a contract with the U.S. Centers for Disease Control and Prevention (CDC) for privacy-preserving record linkage of patient-level real-world healthcare data....
by Truveta staff | Jan 18, 2024 | Data
Crohn’s disease, a complex chronic inflammatory disorder of the GI tract, affects approximately 780,000 Americans with an estimated 33,000 new cases diagnosed each year. Crohn’s, along with ulcerative colitis, are the two major forms of inflammatory bowel disease...
by Truveta staff | Jan 17, 2024 | Technology
The pace of new therapy adoption has been limited by the ability to produce data that the medical community trusts. Clinical researchers have historically had difficulty accessing and cleaning healthcare data, wrestling with hard-to-use tools, and developing and...
by Truveta Research | Jan 11, 2024 | Research, Research Insights
There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and cannabis-involved emergency department visits (both defined below). Between 2019 and 2020, we...
by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
